Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03663387 · ClinicalTrials.gov registry record
PET Measures of CSF Clearance in Preclinical Alzheimer's Disease
A clinical trial, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- 116
- Enrollment target
NCT03663387: Completed study, sponsored by Weill Medical College of Cornell University.
NCT03663387 is a clinical trial that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 116 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03663387 has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- 116 participants
- Enrollment target
Study Summary
The purpose of this study is to measure cerebrospinal fluid (CSF) clearance. CSF cushions the brain from impact and carries waste products from the brain to the bloodstream. This process is known as clearance. Researchers have considered that impaired clearance of amyloid (a protein) from the aging brain causes buildup of amyloid in the brain and plays a role in increased risk for Alzheimer's disease. However, until recently, there has not been a method to measure CSF clearance. This study will examine CSF clearance using positron emission tomography (PET) scanning, which creates images of structures in the body and their functioning. This study will also measure the amount of two proteins, tau and amyloid, in the brain. Tau and amyloid are proteins that build up in the brains of people with Alzheimer's disease. An investigational compound (tracer) called \[18F\]MK-6240 is injected into the blood prior to the scan in order to take images of the CSF clearance and measure tau protein in the brain. This tracer is considered investigational because it is not approved by the US Food and Drug Administration (FDA) for clinical use and is only being used for research purposes.
Primary Outcome
Percent change in brain amyloid measured by positron emission tomography
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2018-07-30 |
| Est. Completion | 2022-08-31 |
What the finished NCT03663387 record still lists
NCT03663387 is an observational study that tracks outcomes without assigning an intervention. The registered 116 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT03663387 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03663387 about?
NCT03663387 is a clinical study titled "PET Measures of CSF Clearance in Preclinical Alzheimer's Disease". The purpose of this study is to measure cerebrospinal fluid (CSF) clearance. CSF cushions the brain from impact and carries waste products from the brain to the bloodstream. This process is known as clearance. Researchers have considered that impaired clearance of amyloid (a protein) from the aging ...
What is the current status of trial NCT03663387?
This trial is currently completed. The enrollment target is 116 participants. The study started on 2018-07-30. Estimated completion is 2022-08-31.
Who is sponsoring clinical trial NCT03663387?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03014687 · 116 participants · Phase 4
Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions
- NCT03214562 · 116 participants · Phase 1
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
- NCT03847467 · 116 participants · Phase 1
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
- NCT04222413 · 116 participants · Phase 1
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI